Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Expression ratio of CCND1 to CDKN2A mRNA predicts RB1 status of cultured cancer cell lines and clinical tumor samples

29 Mar 2011

Abstract excerpt

BACKGROUND: The retinoblastoma product (RB1) is frequently deregulated in various types of tumors by mutation, deletion, or inactivation through association with viral oncoproteins. The functional loss of RB1 is recognized to be one of the hallmarks that differentiate cancer cells from normal cells. Many researchers are attempting to develop anti-tumor agents that are preferentially effective against RB1-negative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Ocular Oncology and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21447152
DOI: 10.1186/1476-4598-10-31

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Expression ratio of CCND1 to CDKN2A mRNA predicts RB1 status of cultured cancer cell lines and clinical tumor samplesPMID 21447152Read ↗

Therapeutic Strategies for RB1-Deficient Cancers: Intersecting Gene Regulation and Targeted TherapySemantic proximity Read ↗

Therapeutic Strategies for RB1-Deficient Cancers: Intersecting Gene Regulation and Targeted TherapySemantic proximity Read ↗

Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics.Semantic proximity Read ↗

High-Level MYCN-Amplified RB1-Proficient Retinoblastoma Tumors Retain Distinct Molecular SignaturesSemantic proximity Read ↗

Pan-cancer molecular analysis of the RB tumor suppressor pathwaySemantic proximity Read ↗

Characterization of NCC-RbC-51, an RB cell line isolated from a metastatic site.Semantic proximity Read ↗

The Use of rAAV2-RB1–Mediated Gene Therapy in RetinoblastomaSemantic proximity Read ↗

Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinomaSemantic proximity Read ↗

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian CancerSemantic proximity Read ↗

CDKN1C (p57KIP2) mRNA expression in human retinoblastomas.Semantic proximity Read ↗

Copy number defects of G1‐Cell cycle genes in neuroblastoma are frequent and correlate with high expression of <i>E2F</i> target genes and a poor prognosisSemantic proximity Read ↗

The Cell Cycle as a Target for Cancer Therapy: Basic and Clinical Findings with the Small Molecule Inhibitors Flavopiridol and UCN-01Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.